Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase III | Biomarker/Laboratory analysis, Prevention | Active | 50 to 74 | Other | ACF:24404 NCT01435005 |
Summary
The Breast Cancer and Exercise Trial (BETA Trial) is a randomized controlled trial aimed at understanding what dose (or volume) of exercise will best reduce a women's risk for breast cancer, particularly women who are between the ages of 50-74. The primary aim is to compare the effects of a high versus moderate volume exercise intervention on specific biological intermediate endpoints for breast cancer in a group of previously inactive postmenopausal women
Eligibility Criteria
Inclusion Criteria:
- Age: 50- 74 years, postmenopausal women
- No previous cancer diagnosis
- Physically fit to undertake exercise program
- Pass the Physical Activity Readiness
- Medical Exam,acceptable heart and lung function during a sub-maximal treadmill test
- Body mass index : 22 - 40
- Non-users of exogenous hormones or drugs related to estrogen metabolism, breast tissue growth
- Non-Smoker and non-excessive alcohol drinkers
- Residents of Calgary and Edmonton able to attend fitness facility regularly.
Exclusion Criteria:
- < 50 years of age
- Diabetes
- Deemed too fit or too unfit on sub-maximal treadmill test
- Non English Speaking
- > 4 consecutive weeks absence during the intervention period
Trial Lead Organizations/Sponsors
Alberta Health Services
| Christine Friedenreich, BSc, MSc,PhD |  | Principal Investigator |
| Sarah MacLaughlin, B.A, MSc. | | Ph: 403-521-3847 |
| Email: Sarah.MacLaughlin@albertahealthservices.ca | ||
Trial Sites
|
|
|
|
| Canada | |||
|
|||
| Alberta | |||
|
|||
| Calgary | |||
|
|||
| Tom Baker Cancer Centre - Calgary | |||
| Sarah MacLaughlin | Ph: 403-521-3847 | ||
| Email: Sarah.MacLaughlin@albertahealthservices.ca | |||
| Christine M Friedenreich, BSc MSc PhD | Principal Investigator | ||
| Edmonton | |||
|
|||
| Cross Cancer Institute at University of Alberta | |||
| Amy E Speed-Andrews, MSc PhD | Ph: 780-492-2663 | ||
| Email: speedand@ualberta.ca | |||
| Kerry S Courneya, BSc, MSc, PhD | Principal Investigator | ||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01435005
Information obtained from ClinicalTrials.gov on January 18, 2012
Back to Top
